ArticleBMC cancer2025
Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Impact of the Indonesian National Health Insurance Implementation on Prostate Cancer Detection, Staging, and Treatment in West Java Province, Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the impact of prostate-specific antigen (PSA) screening on prostate cancer (PCa) characteristics and survival outcomes in a contemporary cohort, amidst evolving PSA screening practices.
methodsWe retrospectively analyzed clinicopathologic data of 5,437 men diagnosed with PCa via prostate biopsy at our institution between 2006 and 2018. Patients were categorized as PSA-detected (PCa detected by PSA testing in asymptomatic individuals) or Symptom-detected (PCa detected after PSA testing prompted by symptoms). Temporal trends in PSA screening and cancer characteristics were assessed using correlation and time-series analyses. Multivariable Cox regression evaluated the effect of PSA screening on overall and cancer-specific survival.
resultsThe PSA screening rate in our cohort increased from 46.4% in 2006 to 63.1% in 2018 (p < 0.001). Greater PSA screening uptake was associated with an increasing proportion of Gleason score 7 tumors (r = 0.608, p = 0.028), more localized-stage disease (r = 0.757, p = 0.003), and fewer cases of distant metastasis at diagnosis (r = -0.605, p = 0.028). The detection of clinically insignificant (low-risk) cancer rose modestly over time (r = 0.437, p = 0.136) but was not significantly influenced by PSA screening rates (r = 0.496, p = 0.085). On multivariate analysis, PSA screening was an independent predictor of improved overall survival (hazard ratio [HR] 0.54, p < 0.001) and cancer-specific survival (HR 0.46, p < 0.001).
conclusionsIncreasing utilization of PSA screening correlated with a stage migration toward localized disease and a reduction in metastatic presentations, without a substantial increase in the detection of clinically insignificant cancer, as defined by Epstein criteria. PSA screening was an independent prognostic factor for better survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.